«Our company BCI has entered into negotiations with the two main industrial partners in the field of biological heart valves – in terms of sales volume» declared Alessandro Gandaglia, CEO of BCI to Fortune.
The greatest benefits of the FACTA Technology developed by BCI are the reduction by 20-30% of the valve replacement surgeries and its consequent decrease of health care expenses.
Read the full article